There are currently 93 clinical trials in Ocala, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Renstar Medical Research, Ocala Oncology Center, Pfizer Investigational Site and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
NCT05758896
Recruiting
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 280 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: Sarkis Clinical Trials, Ocala, Florida
Conditions: Contrast Induced Acute Kidney Injury
Register for Updates
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
NCT05011305
Recruiting
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US081, Ocala, Florida
Conditions: Nonalcoholic Steatohepatitis, Fibrosis
Register for Updates
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
NCT05365490
Recruiting
The study objective is to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System in patients at standard risk for adverse events from carotid endarterectomy
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
11/15/2023
Locations: AdventHealth Ocala, Ocala, Florida
Conditions: Carotid Artery Diseases
Register for Updates
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Ocala, Florida
Conditions: Parkinson Disease
Register for Updates
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
NCT05199818
Recruiting
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: Florida Cancer Affiliates, Ocala, Florida
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Breast Cancer Liquid Biopsy Trial
NCT04962529
Recruiting
The purpose of this study is to continue to develop a liquid biopsy (minimally invasive blood test) that can be used to confirm if breast cancer has spread throughout the body and if this liquid biopsy test can provide comparable information to a highly invasive tissue biopsy. The knowledge gained in this study could be used in future studies to confirm cancer recurrence using a safe and minimally invasive procedure. The research will consist of looking for tumor cell(s) circulating in the blood... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2022
Locations: Ocala Oncology, Ocala, Florida
Conditions: Breast Cancer, Cancer
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Renstar Medical Research -21 NE 1st Ave, Ocala, Florida
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Rib Fixation for Clinically Severe Rib Fractures From Trauma
NCT02595593
Recruiting
This is a multicenter randomized study investigating the differences in clinical outcomes of patients between two standard of care pathways for rib trauma: patients who receive rib fixation versus patients who receive modern critical care and pain control after sustaining clinically significant rib fractures from trauma.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/07/2022
Locations: Ocala Regional Medical Center - Health Trauma, Ocala, Florida
Conditions: Rib Fracture, Flail Chest
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Ocala Oncology, Ocala, Florida
Conditions: Solid Tumors, GI Cancer
Register for Updates